Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Direct-acting antiviral therapy prolongs survival in HCV-infected HCC patients

21 Oct 2019

Use of direct-acting antivirals (DAAs) to treat hepatitis C virus (HCV) in hepatocellular carcinoma (HCC) patients with documented response to therapy appears to yield a significant reduction in mortality, as shown in a recent study.

The retrospective study included 797 patients with HCV-related HCC, among whom 383 (48.1 percent) received DAA therapy. All patients achieved a complete response to resection, local ablation, transarterial chemo- or radioembolization, or radiation therapy.

There were 43 deaths that occurred during 941 person-years of follow-up in the DAA group in comparison with 103 deaths during 526.6 person-years of follow-up in the nontreated group (crude rate ratio, 0.23, 95 percent CI, 0.16–0.33).

Inverse probability-weighted analyses revealed DAA therapy to be associated with a significant decrease in the risk of death (hazard ratio [HR], 0.54, 95 percent CI, 0.33–0.90). This protective association differed by sustained virologic response (SVR) to DAA therapy, such that mortality risk was reduced in patients who achieved SVR (HR, 0.29, 0.18–0.47) but not in those without SVR (HR, 1.13, 0.55–2.33).

Median time from HCC complete response to DAA initiation was 7.7 months, with 20.2 percent of participants treated within 3 months, 21.5 percent between 3 and 6 months, 25.5 percent between 6 and 12 months, and 32.9 percent >12 months after HCC complete response. A total of 79.4 percent of DAA-treated patients achieved SVR, while 11.5 percent had treatment-failure and 9.1 percent had no documented assessment of SVR.

The present data suggest that HCV-infected patients with a history of HCC may benefit from DAA therapies, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.